Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers

J. T C Chang, T. F. Kuo, Y. J. Chen, C. C. Chiu, Y. C. Lu, H. F. Li, C. R. Shen, A. J. Cheng

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Infection with high-risk types (type 16 or type 18) of human papillomaviruses (HPVs) increases a patient's risk of cervical cancer. Given the importance of the cervix and the severe side effects resulting from traditional cancer therapies, this study aimed to achieve targeted inhibition of viral oncogenes in tumor cells using small interfering RNAs (siRNA). To accomplish this, we developed nine siRNAs against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations, yielding siRNAs targeting 16E6, 16E7, 18E6 and 18E7. We measured the effectiveness of the siRNAs by examining E6 or E7 mRNA expression after transfection of the siRNAs into HPV-positive CaSki (HPV-16) or HeLa (HPV-18) cell lines. We found that the HPV-siRNAs significantly reduced cell growth and colony formation in both cell lines. Flow cytometry analysis revealed a significant increase in apoptosis. The siRNAs had no effect on cell growth, colony formation or apoptosis in HPV-negative C33A cells, demonstrating a lack of off-target effects. In addition, an in vivo xenograft study showed that intra-tumoral injection of the siRNAs reduced tumor growth in BALB/c nude mice. In conclusion, we have developed highly specific and potent HPV-siRNAs that successfully suppress tumor growth and induce apoptosis in HPV-positive cervical cancer cells. siRNA treatment has potential for further development as an adjuvant therapy for cervical cancer.

Original languageEnglish
Pages (from-to)827-836
Number of pages10
JournalCancer Gene Therapy
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 2010
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Human papillomavirus 18
Human papillomavirus 16
Genes
Apoptosis
Growth
Small Interfering RNA
Neoplasms
Cell Line
Oncogenes
Heterografts
Nude Mice
Cervix Uteri
Transfection
Flow Cytometry
Therapeutics
Messenger RNA
Injections
Infection

Keywords

  • cervical cancer
  • E6
  • E7
  • HPV
  • siRNA silencing

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers. / Chang, J. T C; Kuo, T. F.; Chen, Y. J.; Chiu, C. C.; Lu, Y. C.; Li, H. F.; Shen, C. R.; Cheng, A. J.

In: Cancer Gene Therapy, Vol. 17, No. 12, 12.2010, p. 827-836.

Research output: Contribution to journalArticle

Chang, JTC, Kuo, TF, Chen, YJ, Chiu, CC, Lu, YC, Li, HF, Shen, CR & Cheng, AJ 2010, 'Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers', Cancer Gene Therapy, vol. 17, no. 12, pp. 827-836. https://doi.org/10.1038/cgt.2010.38
Chang, J. T C ; Kuo, T. F. ; Chen, Y. J. ; Chiu, C. C. ; Lu, Y. C. ; Li, H. F. ; Shen, C. R. ; Cheng, A. J. / Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers. In: Cancer Gene Therapy. 2010 ; Vol. 17, No. 12. pp. 827-836.
@article{95f921c8550e4dd1bf435e7dc49e316b,
title = "Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers",
abstract = "Infection with high-risk types (type 16 or type 18) of human papillomaviruses (HPVs) increases a patient's risk of cervical cancer. Given the importance of the cervix and the severe side effects resulting from traditional cancer therapies, this study aimed to achieve targeted inhibition of viral oncogenes in tumor cells using small interfering RNAs (siRNA). To accomplish this, we developed nine siRNAs against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations, yielding siRNAs targeting 16E6, 16E7, 18E6 and 18E7. We measured the effectiveness of the siRNAs by examining E6 or E7 mRNA expression after transfection of the siRNAs into HPV-positive CaSki (HPV-16) or HeLa (HPV-18) cell lines. We found that the HPV-siRNAs significantly reduced cell growth and colony formation in both cell lines. Flow cytometry analysis revealed a significant increase in apoptosis. The siRNAs had no effect on cell growth, colony formation or apoptosis in HPV-negative C33A cells, demonstrating a lack of off-target effects. In addition, an in vivo xenograft study showed that intra-tumoral injection of the siRNAs reduced tumor growth in BALB/c nude mice. In conclusion, we have developed highly specific and potent HPV-siRNAs that successfully suppress tumor growth and induce apoptosis in HPV-positive cervical cancer cells. siRNA treatment has potential for further development as an adjuvant therapy for cervical cancer.",
keywords = "cervical cancer, E6, E7, HPV, siRNA silencing",
author = "Chang, {J. T C} and Kuo, {T. F.} and Chen, {Y. J.} and Chiu, {C. C.} and Lu, {Y. C.} and Li, {H. F.} and Shen, {C. R.} and Cheng, {A. J.}",
year = "2010",
month = "12",
doi = "10.1038/cgt.2010.38",
language = "English",
volume = "17",
pages = "827--836",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers

AU - Chang, J. T C

AU - Kuo, T. F.

AU - Chen, Y. J.

AU - Chiu, C. C.

AU - Lu, Y. C.

AU - Li, H. F.

AU - Shen, C. R.

AU - Cheng, A. J.

PY - 2010/12

Y1 - 2010/12

N2 - Infection with high-risk types (type 16 or type 18) of human papillomaviruses (HPVs) increases a patient's risk of cervical cancer. Given the importance of the cervix and the severe side effects resulting from traditional cancer therapies, this study aimed to achieve targeted inhibition of viral oncogenes in tumor cells using small interfering RNAs (siRNA). To accomplish this, we developed nine siRNAs against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations, yielding siRNAs targeting 16E6, 16E7, 18E6 and 18E7. We measured the effectiveness of the siRNAs by examining E6 or E7 mRNA expression after transfection of the siRNAs into HPV-positive CaSki (HPV-16) or HeLa (HPV-18) cell lines. We found that the HPV-siRNAs significantly reduced cell growth and colony formation in both cell lines. Flow cytometry analysis revealed a significant increase in apoptosis. The siRNAs had no effect on cell growth, colony formation or apoptosis in HPV-negative C33A cells, demonstrating a lack of off-target effects. In addition, an in vivo xenograft study showed that intra-tumoral injection of the siRNAs reduced tumor growth in BALB/c nude mice. In conclusion, we have developed highly specific and potent HPV-siRNAs that successfully suppress tumor growth and induce apoptosis in HPV-positive cervical cancer cells. siRNA treatment has potential for further development as an adjuvant therapy for cervical cancer.

AB - Infection with high-risk types (type 16 or type 18) of human papillomaviruses (HPVs) increases a patient's risk of cervical cancer. Given the importance of the cervix and the severe side effects resulting from traditional cancer therapies, this study aimed to achieve targeted inhibition of viral oncogenes in tumor cells using small interfering RNAs (siRNA). To accomplish this, we developed nine siRNAs against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations, yielding siRNAs targeting 16E6, 16E7, 18E6 and 18E7. We measured the effectiveness of the siRNAs by examining E6 or E7 mRNA expression after transfection of the siRNAs into HPV-positive CaSki (HPV-16) or HeLa (HPV-18) cell lines. We found that the HPV-siRNAs significantly reduced cell growth and colony formation in both cell lines. Flow cytometry analysis revealed a significant increase in apoptosis. The siRNAs had no effect on cell growth, colony formation or apoptosis in HPV-negative C33A cells, demonstrating a lack of off-target effects. In addition, an in vivo xenograft study showed that intra-tumoral injection of the siRNAs reduced tumor growth in BALB/c nude mice. In conclusion, we have developed highly specific and potent HPV-siRNAs that successfully suppress tumor growth and induce apoptosis in HPV-positive cervical cancer cells. siRNA treatment has potential for further development as an adjuvant therapy for cervical cancer.

KW - cervical cancer

KW - E6

KW - E7

KW - HPV

KW - siRNA silencing

UR - http://www.scopus.com/inward/record.url?scp=78349311997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349311997&partnerID=8YFLogxK

U2 - 10.1038/cgt.2010.38

DO - 10.1038/cgt.2010.38

M3 - Article

C2 - 20885450

AN - SCOPUS:78349311997

VL - 17

SP - 827

EP - 836

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 12

ER -